News See the latest press releases about Pentixapharm. Ad-hoc announcement Sebastian Bloszyk 5/27/25 Ad-hoc announcement Sebastian Bloszyk 5/27/25 Pentixapharm outlines new clinical development strategy Read More Ad-hoc announcement Phillip Eckert 1/24/25 Ad-hoc announcement Phillip Eckert 1/24/25 Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million Read More Ad-hoc announcement Phillip Eckert 10/18/24 Ad-hoc announcement Phillip Eckert 10/18/24 EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor Read More Ad-hoc announcement Phillip Eckert 10/1/24 Ad-hoc announcement Phillip Eckert 10/1/24 Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed Read More
Ad-hoc announcement Sebastian Bloszyk 5/27/25 Ad-hoc announcement Sebastian Bloszyk 5/27/25 Pentixapharm outlines new clinical development strategy Read More
Ad-hoc announcement Phillip Eckert 1/24/25 Ad-hoc announcement Phillip Eckert 1/24/25 Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million Read More
Ad-hoc announcement Phillip Eckert 10/18/24 Ad-hoc announcement Phillip Eckert 10/18/24 EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor Read More
Ad-hoc announcement Phillip Eckert 10/1/24 Ad-hoc announcement Phillip Eckert 10/1/24 Pentixapharm Holding AG: Placement Price Set at EUR 5.10 per Share, All 3.9 Million Offer Shares Placed Read More
